Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 31

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 31
---
 the issuance of shares of our Common Stock pursuant to the Private Placement. If our stockholders approve the issuance of the Warrants and the adjustment provisions of the Warrants, the exercise of the Warrants (assuming the exercise price has been reset to the Floor Price of $0.132) could result in the issuance of up to an additional approximately 1,542,317,700 shares of our Common Stock. In addition, following the approval and filing of the Certificate of Amendment, the Company may explore additional financing opportunities or strategic transactions that would require the issuance of additional shares of Common Stock, but no such plans are currently in existence and the Company has not begun any negotiations with any party related thereto. If we issue additional shares, the ownership interest of holders of our capital stock will be diluted. Other than as set forth above, the Company has no current plans, proposals or arrangements to issue any of the additional authorized shares of Common Stock that would become available as a result of the filing of the Certificate of Amendment.

18

#### TABLE OF CONTENTS
**Effects of the Increase in Authorized Common Stock**

Following the filing of the Certificate of Amendment with the Secretary of State of Delaware, we will have the authority to issue up to 2,000,000,000 shares of Common Stock. These shares may be issued without stockholder approval at any time (except as such approval may be required in particular cases by our charter documents, applicable law or the rules of any stock exchange on which our securities may then be listed), in the sole discretion of the Board. The authorized and unissued shares may be issued for cash or for any other purpose that is deemed in the best interests of the Company.

The increase in our authorized Common Stock could have a number of effects on the Company’s stockholders depending upon the exact nature and circumstances of any actual issuances of authorized but unissued shares. If we issue additional shares of Common Stock or other securities convertible into shares of our Common Stock in the future, it could dilute the voting rights of existing stockholders and could also dilute earnings per share and book value per share of existing stockholders. The increase in authorized number of Common Stock could also discourage or hinder efforts by other parties to obtain control of the Company, thereby having an anti-takeover effect.

The increase in our authorized Common Stock will not have any immediate dilutive effect or change the rights of current holders of our Common Stock.

**Procedure for Implementing the Increase in Authorized Common Stock**

The increase in our authorized Common Stock will become